AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26024531
Drug: MiCK drug-induced
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MiCK drug-induced apoptosis assay (used by physicians)
Trial: 26025572
Drug: Prasugrel 10
RxNorm normalized name: prasugrel 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 10 mg od
Trial: 26025807
Drug: 4CMenB vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4CMenB vaccine administered at 0, 2, and 6 months
Trial: 26025807
Drug: ACWY-CRM vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACWY-CRM vaccine administered concomitantly at 0 months
Trial: 26025933
Drug: Bevacizumab (BV)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab (BV) at 10 mg/kg every 2 weeks, Temozolomide (TMZ) at 200 mg/m² per day on days 1-5, Irinotecan (CPT-11) at 125 mg/m² or 340 mg/m² every 2 weeks depending on antiepileptic drugs.
Trial: 26025965
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg daily and Everolimus 5 mg daily until disease progression, intolerable toxicity, investigator or patient decision.
Trial: 26026738
Drug: hu3S193 (20mg/m²
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hu3S193 (20mg/m² intravenously weekly for 8 weeks, up to 3 cycles)
Trial: 26028255
Drug: Pembrolizumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (10 mg/kg every 14 days) in mismatch repair-deficient colorectal cancers
Trial: 26028255
Drug: Pembrolizumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (10 mg/kg every 14 days) in mismatch repair-proficient colorectal cancers
Trial: 26028255
Drug: Pembrolizumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (10 mg/kg every 14 days) in mismatch repair-deficient non-colorectal cancers
Trial: 26028965
Drug: Anagrelide therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anagrelide therapy in JAK2-positive patients
Trial: 26028965
Drug: Anagrelide therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anagrelide therapy in JAK2-negative patients
Trial: 26028965
Drug: Anagrelide therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anagrelide therapy in JAK2-positive patients (last observation carried forward)
Trial: 26028965
Drug: Anagrelide therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anagrelide therapy in JAK2-negative patients (last observation carried forward)
Trial: 26031269
Drug: Preincision gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preincision gentamicin injection
Trial: 26033282
Drug: CBD 300
RxNorm normalized name: MENTHOL, UNSPECIFIED FORM 10 g in 100 g / CAMPHOR (SYNTHETIC) 3 g in 100 g TOPICAL CREAM [ETERNAL SPIRIT BEAUTY PAINLESS WITH CBD 3000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD 300 mg/day given orally starting 7 days before transplantation until day 30
Trial: 26037794
Drug: Implantable cardioverter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy-defibrillator (CRT-D) implant
Trial: 26038709
Drug: Troponin T
RxNorm normalized name: Troponin T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troponin T > 0.05 ng/mL
Trial: 26040252
Drug: Mobile app
RxNorm normalized name: Mahana IBS CBT Mobile Application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile app follow-up care using QoR9, VAS, surgery-specific questions, and surgical site photos submitted daily for the first 2 weeks and weekly for the following 2 weeks.
Trial: 26040622
Drug: Ixabepilone (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixabepilone (6 mg/m² per day for 5 days every 21 days)
Trial: 26040640
Drug: Mathematical model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mathematical model of human metabolism
Trial: 26041763
Drug: Aplidin 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aplidin 5 mg/m(2) days 1-15, 28-day cycle until disease progression or unacceptable toxicity
Trial: 26043810
Drug: velaglucerase alfa
RxNorm normalized name: Velaglucerase alfa
DrugBank: Velaglucerase alfa (DB06720)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: velaglucerase alfa 30-60U/kg by intravenous infusion every other week
Trial: 26044316
Drug: Magnetic sphincter
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnetic sphincter augmentation device
Trial: 26046067
Drug: Intratumoral injection
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intratumoral injection of Clostridium novyi-NT spores
Trial: 26048686
Drug: High caloric
RxNorm normalized name: high caloric supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High caloric (428 kcal) (13)C-Sodium Octanoate breath test OFF dopaminergic medication
Trial: 26048686
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral Levodopa/25 mg Benserazide
Trial: 26049121
Drug: Intraperitoneal catumaxomab
RxNorm normalized name: catumaxomab
DrugBank: Catumaxomab (DB06607)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal catumaxomab infusion
Trial: 26049781
Drug: 2 μg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 μg/mL TCI propofol
Trial: 26049781
Drug: 3 μg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 μg/mL TCI propofol
Trial: 26049781
Drug: 4 μg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 μg/mL TCI propofol
Trial: 26049896
Drug: Olipudase alfa
RxNorm normalized name: OLIPUDASE ALFA
DrugBank: Olipudase alfa (DB12835)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olipudase alfa (0.1 to 3.0 mg/kg, intravenously every 2 weeks for 26 weeks)
Trial: 26053994
Drug: General anaesthetic
RxNorm normalized name: General anaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anaesthetic agents (halogenated agents or propofol)
Trial: 26059242
Drug: Bone marrow-derived
RxNorm normalized name: Allogeneic human bone marrow-derived mpc
DrugBank: Rexlemestrocel-L (DB17606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow-derived mononuclear cells (BMDMCs) administered through bronchoscopy (2 × 10(7) cells)
Trial: 26059948
Drug: Ibrutinib 560
RxNorm normalized name: ibrutinib 560 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 560 mg once daily
Trial: 26062135
Drug: Imaginal exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imaginal exposure for PTSD with dialectical behavior therapy
Trial: 26062823
Drug: Anaplastic lymphoma
RxNorm normalized name: Anaplastic lymphoma kinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anaplastic lymphoma kinase (ALK) inhibitor (crizotinib/Xalkori®) and a multikinase VEGF inhibitor (pazopanib/Votrient®)
Trial: 26063065
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g tomato puree providing 0.4 mg β-carotene
Trial: 26063065
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 25 SNPs in 12 genes
Trial: 26063067
Drug: B vitamin-containing
RxNorm normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: B vitamin-containing supplements
Trial: 26063483
Drug: Birth preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Birth preparation
Trial: 26063633
Drug: Pazopanib as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib as a single agent
Trial: 26064113
Drug: 2-week continuous
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week continuous administration of a protein-based formula (1.2 g/kg of ideal body weight/day) by nasogastric tube
Trial: 26064113
Drug: 2-week continuous
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week continuous administration of a protein-based formula
Trial: 26064192
Drug: semagacestat (γ-secretase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: semagacestat (γ-secretase inhibitor)
Trial: 26065566
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (adenotonsillectomy)
Trial: 26065566
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (non-OSAS)
Trial: 26065566
Drug: RDI at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RDI at T0 and increase in BMI as risk factors for persistent OSAS in dietary treatment
Trial: 26065651
Drug: Nilotinib plus
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib plus multiagent chemotherapy (vincristine, daunorubicin, prednisolone) during induction treatment
Trial: 26065651
Drug: Nilotinib plus
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib plus multiagent chemotherapy
Trial: 26065651
Drug: Nilotinib combined
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib combined with high-dose cytotoxic drugs
Trial: 26066765
Drug: Romiplostim treatment
RxNorm normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Romiplostim treatment for up to 4 years
Trial: 26069234
Drug: Circulating FABP4
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Circulating FABP4 in patients with ST-segment-elevation myocardial infarction (24.9 ng/mL)
Trial: 26070683
Drug: Dovitinib (TKI258),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dovitinib (TKI258), 500mg orally once daily for five consecutive days, followed by a 2-day rest every week
Trial: 26071053
Drug: R-CHOP treatment
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP treatment (rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone) followed by two cycles of R (R-CHOP-14)
Trial: 26071053
Drug: R-CHOP treatment
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP treatment
Trial: 26071868
Drug: Vorinostat (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorinostat (200 mg/day to 1000 mg/day, days -8 to -3) + Gemcitabine (10 mg/m²/minute over 4.5 hours, days -8 and -3) + Busulfan (targeted 4000 μM-minute/day, days -8 to -5) + Melphalan (60 mg/m²/day, days -3 and -2) + Rituximab (375 mg/m², days +1 and +8 for CD20(+) tumors)
Trial: 26072149
Drug: Daptomycin at
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daptomycin at 4 mg/kg/day
Trial: 26072932
Drug: 5-Ling Granule
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-Ling Granule (15-22.5 g/day)
Trial: 26072932
Drug: Tiapride (200-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiapride (200-400 mg/day)
Trial: 26073352
Drug: Alisertib oral
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisertib oral solution (OS) 25 mg
Trial: 26073352
Drug: Alisertib powder-in-capsule
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisertib powder-in-capsule (PIC) 50 mg
Trial: 26073352
Drug: Alisertib oral
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisertib oral solution (OS)
Trial: 26073352
Drug: Alisertib powder-in-capsule
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisertib powder-in-capsule (PIC)
Trial: 26073451
Drug: KRN23 (0.05,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KRN23 (0.05, 0.10 ± 0.01, 0.28 ± 0.06, and 0.48 ± 0.16 mg/kg administered subcutaneously every 28 days)
Trial: 26075081
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of phylloquinone three times per week
Trial: 26075081
Drug: Placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration three times per week
Trial: 26075496
Drug: Novel TNXB
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel TNXB missense variant c.12174C>G (p.C4058W)
Trial: 26077240
Drug: Alisertib 50
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisertib 50 mg twice a day for 7 days on 21-day cycles
Trial: 26077415
Drug: Antihistamine premedication
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistamine premedication
Trial: 26077415
Drug: Concomitant immunosuppressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant immunosuppressant or corticosteroids
Trial: 26077415
Drug: Antihistamines, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistamines, intravenous steroids, and acetaminophen as preventative premedication
Trial: 26079776
Drug: Short-term Intensive
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term Intensive Insulin Therapy (IIT) for 4 weeks, consisting of basal detemir and premeal insulin aspart.
Trial: 26082332
Drug: Onalespib (AT13387)
RxNorm normalized name: Onalespib
DrugBank: Onalespib (DB06306)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onalespib (AT13387) at RP2D of 160 mg/m(2)/dose administered on days 1, 2, 8, 9, 15, and 16 of 28 day cycles (QDx2/week)
Trial: 26082464
Drug: Ingestion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingestion of virulent S. Paratyphi A bacteria (NVGH308 strain) with a bicarbonate buffer solution to establish the infectious dose.
Trial: 26082815
Drug: Oral levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral levosimendan (0.125 to 2.0 mg daily for 18-day intervals)
Trial: 26082815
Drug: Oral levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral levosimendan (≥0.5 mg)
Trial: 26082815
Drug: Oral levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral levosimendan (2.0 mg)
Trial: 26082920
Drug: Novel brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel brain and vestibular rehabilitation (VR) treatment for PTSD
Trial: 26083135
Drug: Adaptive model-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive model-based dose-ranging trial
Trial: 26083256
Drug: Lapatinib 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib 1500 mg daily in monthly cycles
Trial: 26083430
Drug: Therapeutic plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic plasma exchanges (TPE) and rituximab, supplemented with intravenous immunoglobulin (IVIG) in later cases
Trial: 26083430
Drug: Conventional glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional glucocorticoid therapy
Trial: 26084934
Drug: Stress Doppler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stress Doppler echocardiography (SDE) during low-dose exercise
Trial: 26084989
Drug: Alisertib 30
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisertib 30 mg BID
Trial: 26084989
Drug: Alisertib 40
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisertib 40 mg BID
Trial: 26084990
Drug: Oral MK-2206
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral MK-2206 at a dose of 200 mg administered on days 1, 8, 15, and 22 of a 28-day cycle until progression.
Trial: 26088649
Drug: Perioperative goal-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative goal-directed therapy (PGDT) with standardized baseline crystalloid administration of 3 ml/kg/hour and additional boluses based on PGDT.
Trial: 26088649
Drug: Perioperative goal-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative goal-directed therapy (PGDT) implementation.
Trial: 26088933
Drug: Ruxolitinib 15
RxNorm normalized name: ruxolitinib 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib 15 mg orally twice daily plus lenalidomide 5 mg orally once daily on days 1-21
Trial: 26088933
Drug: Ruxolitinib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib and lenalidomide combination therapy
Trial: 26089222
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg of oral solithromycin
Trial: 26089222
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of oral solithromycin
Trial: 26089222
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of solithromycin (1200 mg and 1000 mg)
Trial: 26089397
Drug: Combination chemoimmunotherapy
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemoimmunotherapy with doxorubicin- and rituximab-based regimens; 93 patients received consolidation radiotherapy.
Trial: 26091915
Drug: Ridaforolimus 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ridaforolimus 20 mg daily days 1-5 with vorinostat 100 mg BID days 1-3 weekly (MTD)
Trial: 26091915
Drug: Ridaforolimus 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ridaforolimus 20 mg daily days 1-5 with vorinostat 100 mg daily days 1-3 weekly (recommended phase II dose)
Trial: 26092537
Drug: Fingolimod therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod therapy
Trial: 26093865
Drug: Secondary prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secondary prevention medications (aspirin, adenosine diphosphate receptor inhibitors, β-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, statins)
Trial: 26094614
Drug: L-asparaginase encapsulated
RxNorm normalized name: L-asparaginase encapsulated in red blood cells
DrugBank: Red blood cell-encapsulated L-asparaginase (DB17477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-asparaginase encapsulated in erythrocytes (GRASPA®) at 100 IU/kg
Trial: 26094614
Drug: L-asparaginase encapsulated
RxNorm normalized name: L-asparaginase encapsulated in red blood cells
DrugBank: Red blood cell-encapsulated L-asparaginase (DB17477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-asparaginase encapsulated in erythrocytes (GRASPA®) at 150 IU/kg
Trial: 26094614
Drug: L-asparaginase encapsulated
RxNorm normalized name: L-asparaginase encapsulated in red blood cells
DrugBank: Red blood cell-encapsulated L-asparaginase (DB17477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-asparaginase encapsulated in erythrocytes (GRASPA®) at 50 IU/kg
Trial: 26094614
Drug: L-asparaginase encapsulated
RxNorm normalized name: L-asparaginase encapsulated in red blood cells
DrugBank: Red blood cell-encapsulated L-asparaginase (DB17477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-asparaginase encapsulated in erythrocytes (GRASPA®)
Trial: 26094738
Drug: Pegylated interferon-alpha
RxNorm normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon-alpha plus ribavirin (PegIFN/RBV) therapy
Trial: 26094738
Drug: Non-responders with
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-responders with high MICA level (>100 pg/mL)
Trial: 26095521
Drug: Enzyme replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme replacement therapy for attenuated MPS I
Trial: 26095669
Drug: Alefacept (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alefacept (0.25 mg/kg/dose on days -40 and -9; 0.5 mg/kg/dose on days -33, -26, -19, and -12)
Trial: 28693366
Drug: Idarucizumab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarucizumab (5 g intravenous)
Trial: 26095785
Drug: Concurrent radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent radiotherapy (35 Gy in ten fractions, over 2 weeks) and granulocyte-macrophage colony-stimulating factor (125 μg/m(2) subcutaneously injected daily for 2 weeks, starting during the second week of radiotherapy)
Trial: 26095785
Drug: Concurrent radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent radiotherapy and granulocyte-macrophage colony-stimulating factor
Trial: 26097680
Drug: 300IR 5-grass
RxNorm normalized name: Buffalo grass
DrugBank: Anthoxanthum odoratum (DB14163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300IR 5-grass pollen tablet (2 months prior to pollen season)
Trial: 26097680
Drug: 300IR 5-grass
RxNorm normalized name: Buffalo grass
DrugBank: Anthoxanthum odoratum (DB14163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300IR 5-grass pollen tablet (4 months prior to pollen season)
Trial: 26097680
Drug: Secondary efficacy
RxNorm normalized name: Secondary potassium phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secondary efficacy measures (both post-treatment years)
Trial: 26097986
Drug: AZD3043 1-minute
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3043 1-minute bolus IV infusion (1, 1.5, 2, 4, and 6 mg/kg)